The global antibody-drug conjugates (ADCs) market size was significantly large in 2020, and is expected to continue to register a rapidly inclining revenue CAGR between 2021 and 2030. Key factors responsible for driving market revenue growth are various advantages of antibody-drug conjugates over conventional treatment options for cancer and increasing prevalence of cancer across the globe. Rising cases of cancer is further surging the need for more robust and effective cancer treatment, which, in turn, is set to propel market growth. Cancer Research UK, for instance, declared that during 2015 to 2017, on an average 36% people belonging to the age group of 75 years and above contracted new cancer cases. The organization estimated that this number is likely to increase to almost 46% till 2035 for the same age group.
Antibody-drug conjugates are new kind of targeted drugs comprising of three parts, namely, monoclonal antibodies (mABs) for binding, cytotoxic drugs to kill targeted cancer cells, and linkers for linking cytotoxic drugs to the antibody, thereby forming a single unified structure. The main purpose of developing antibody-drug conjugates is to target only cancerous tumor cells and not harm other healthy systemic cells in the process. Antibody-drug conjugate was designed to increase effectiveness and reduce toxicity of chemotherapy. It also has dual ability of targeting the cancer cell and killing it with cytotoxic drugs. Antibody-drug conjugate has become an ideal method for treating cancer, owing to biotechnological advancements and innovations. When the cytotoxic drug is embedded as antibody-drug conjugate, its effectiveness increases by almost hundred to thousand times than if it were to act alone on cancer cells.
Major Factors Driving Growth of The Global Antibody-drug Conjugates Market:
Revenue growth of the global antibody-drug conjugates market is significantly rising because of several encouraging factors. Increasing number of cancer patients due to changes in lifestyles, increasing cases of obesity, and rising geriatric population worldwide are expected to propel the antibody-drug conjugates market share in the forthcoming years. Healthcare facilities are nowadays using new treatment method of immunotherapy by replacing conventional chemotherapy and radiation. Also, government support for oncology research associated with various types of cancer, increasing immune response treatments, & partnerships between biopharmaceutical & biotechnology firms to create lifesaving cancer medicines are set to drive the antibody-drug conjugates market growth in the near future.
Factors Restraining Growth of The Global Antibody-drug Conjugates Market:
The global antibody-drug conjugates market growth is substantially hampered by several unfavorable factors. Price of the drug and treatment procedures involve a lot of cost spending. Besides, lack of sufficient funds and requirement of high investments for research activities may also hamper market growth significantly.
Opportunities For Players Operating in The Global Antibody-drug Conjugates Market:
Leading biopharmaceutical and biotechnology companies are expected to gain new growth opportunities in the antibody-drug conjugates market, owing to rising number of cancer cases across the globe. Most of these companies are putting in tremendous efforts to develop new treatment therapies and drug discoveries to treat cancer patients with unique antibody-drug conjugates. Innovations in this market is also expected to create new opportunities for key players and new entrants in the near future. Moreover, most of the companies are engaging in mergers and acquisitions to make use of each other’s expertise for developing state-of-the-art products associated with cancer therapies and drugs.
Global Antibody-drug Conjugates Market Revenue Led by Technology Segment:
Based on technology, THE cleavable linker segment currently dominates the antibody-drug conjugates market because of its efficient cytotoxic drug release mechanism and proven record of treatment therapies. Its split mechanism helps in fast action at the targeted point of release, thereby giving it an edge over non-cleavable and linker less technology.
Global Antibody-drug Conjugates Market Leading Application Segment:
Based on application, the breast cancer segment dominates the antibody-drug conjugates market. According to the World Health Organization (WHO), in 2020, there were around 2.26 million cases of breast cancer. Till date, two antibody-drug conjugates have been successfully approved by the US FDA for treatment of HER2-positive breast cancer patients, namely Kadcyla and Enhertu.
North America Accounts for Largest Revenue Share in Global Antibody-drug Conjugates Market:
North America holds a major share of the antibody-drug conjugates market in terms of revenue as it is the home to most advanced healthcare systems. Presence of various renowned manufacturers of advanced cancer drugs, especially in developing countries, such as Canada and the United States is also anticipated to propel antibody-drug conjugates market growth. These companies are persistently spending huge sums in R&D activities to develop novel drugs in the healthcare sectors.
Asia Pacific Continues to Lead in Terms of Revenue CAGR:
Asia Pacific antibody-drug conjugates market is expected to register the fastest CAGR over the forecast period. High population growth in this region is directly proportional to the number of cancer cases. Globocan, for instance, reported that approximately 49.2% of global cancer cases were registered in Asia in 2020. Hence, antibody-drug conjugates are expected to showcase high demand over the forecast period in Asia Pacific.
Major Companies Profiled in The Report:
Strategies And Objectives of Major Companies:
What Our Report Provides and Why Our Offering Is Better:
This report offers historical data points and forecasts and revenue growth at a global, regional, and country level, and provides analysis, industry trends, and consumption pattern details for each region, major country, and segment from 2019 to 2030. The global market report includes industry trends, drivers, restraints, opportunities, threats, market strategies, segment revenue, and market share contribution by each regional and country market. In addition, the report offers industry analysis and competitive landscape, company financials, and impact analysis. The report includes a detailed view of the global market, along with changing dynamics and trends, scenarios, detailed market and regional segmentation, regional landscape, analysis and evaluation, major investments, product offerings, product launches, and details of historical, current, and projected revenues.
Detailed Segmentation in Our Report:
For the purpose of this report, global antibody-drug conjugates market is segmented on the basis of technology, application, end-use, and region:
By Technology Outlook (Revenue, USD Billion; 2019-2030)
By Application Outlook (Revenue, USD Billion; 2019-2030)
By End-use Outlook (Revenue, USD Billion; 2019-2030)
Region Outlook (Revenue, USD Billion; 2019-2030)
Some points on how the report benefits stakeholders: